Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib PK in Healthy Participants
NCT06505265Phase 1Completed
- Sponsor
- Incyte
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), Vitiligo and prurigo nodularis (PN), sponsored by Incyte. Primary endpoints: Pharmacokinetic (PK) in dermal povorcitinib and PK in plasma povorcitinib. Started Aug 2024; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)Vitiligoprurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06505265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505265.